[Successful therapy of discoid lupus erythematosus with efalizumab].
The therapy of discoid lupus erythematosus (DLE) is occasionally a therapeutic challenge. Topical treatment is often not sufficient and therapy with antimalarials [(hydroxy-) chloroquine] not always successful. We report on a 50-year-old male patient with recalcitrant chronic DLE who experienced within 12 weeks at first improvement and then almost complete remission for 11 months after off-label application of the anti-CD11a antibody efalizumab.
Booken
N
N
Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68135, Mannheim. nina.booken@haut.ma.uni-heidelberg.de
Schumann
T
T
Fuchslocher
M
M
Goerdt
S
S
Goebeler
M
M
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D008179:Lupus Erythematosus, Discoid / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab